文献速递肿瘤 PET/CT神经核医学

胃泌素释放肽受体靶向PET显像在肿瘤学中的诊断价值:一项系统综述

Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review.
PubMed 文献 · Semin Nucl Med · 2025-01-24

该系统综述检索主要医学数据库至2024年5月23日,最终纳入38项研究,评估胃泌素释放肽受体(GRPR)靶向PET在乳腺癌、前列腺癌、胃肠道间质瘤(GIST)和胶质瘤中的诊断价值。GRPR靶向PET在雌激素受体(ER)阳性乳腺癌、前列腺癌和胶质瘤中显示出应用前景,可能改善临床决策。

要点

  • GRPR靶向PET可有效检出乳腺癌原发灶和转移灶,尤其在ER阳性患者中,并可预测治疗反应。
  • 前列腺癌原发灶检出灵敏度高达88%、特异度高达90%,联合MRI具附加价值;生化复发中PSA低于0.5ng/dL亦可定位病灶。
  • 胶质瘤中GRPR靶向PET以MRI为参考达到100%检出率,有助于定位、术前规划及鉴别复发与恶性转化。

核心结论

  • GRPR靶向PET在改善肿瘤诊断方面显示出应用前景,尤其在ER阳性乳腺癌、前列腺癌和胶质瘤中,并可能增强临床决策。

研究设计与样本

  • 系统综述,检索主要医学数据库截至2024年5月23日,初始检索1624项研究,107项进入全文审查,最终38项研究符合纳入标准。

主要发现

  • 乳腺癌中GRPR靶向PET有效检出原发肿瘤和转移灶,尤其在ER阳性患者中,并可预测治疗反应。
  • 前列腺癌中原发肿瘤检出灵敏度高达88%、特异度高达90%,联合MRI具附加价值;生化复发中PSA低于0.5ng/dL亦可识别病灶。
  • 与PSMA PET相比,GRPR靶向PET显示相当或更优的检出率。
  • GIST中GRPR靶向PET为有价值的诊断工具,尤其当[18F]FDG PET结果不确定时。
  • 胶质瘤中GRPR靶向PET以MRI为参考达到100%检出率,有助于定位、术前规划及鉴别复发与恶性转化。

关键数值与推荐

  • 前列腺癌原发肿瘤检出灵敏度高达88%、特异度高达90%。
  • 生化复发中可在PSA低于0.5ng/dL时识别前列腺癌病灶。
  • 胶质瘤中GRPR靶向PET以MRI为参考检出率为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastrin-releasing peptide receptor (GRPR), overexpressed in various cancers, is a promising target for positron emission tomography (PET). This systematic review investigated the diagnostic value of GRPR-targeted PET imaging in oncology. A systematic search was conducted on major medical databases until May 23, 2024. Keywords were modified to include clinical original studies on GRPR-targeted PET in cancer patients. Out of 1624 searched studies initially, 107 were eligible for the full-text review. Overall, data from 38 studies met inclusion criteria, investigating GRPR-targeting radiotracers in breast cancer, prostate cancer, gastrointestinal stromal tumours (GIST) and gliomas (including optic pathway glioma and glioblastoma multiforme). In breast cancer, GRPR-targeted PET effectively detected primary tumours and metastases, particularly in estrogen receptor (ER)-positive patients, and predicted treatment response. In prostate cancer, high sensitivity (up to 88%) and specificity (up to 90%) for detecting primary tumours were observed, providing added value when combined with magnetic resonance imaging (MRI). In biochemical recurrence, sites of prostate cancer were identified even at PSA levels below 0.5ng/dL. Compared with PSMA PET, GRPR-targeted PET showed comparable or superior detection rates. Considering GIST, GRPR-targeted PET imaging proved to be a valuable diagnostic tool, particularly when [18F] FDG PET results were inconclusive. Regarding gliomas, GRPR-targeted PET achieved a 100% detection rate (MRI reference), aiding localization, preoperative planning, and differentiation between recurrence and malignant transformation. GRPR-targeted PET shows promise in improving cancer diagnostics, particularly in ER-positive breast cancer, prostate cancer, and gliomas, and may enhance clinical decision-making.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mohseninia N, Eisazadeh R, Mirshahvalad SA, et al. Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review. Semin Nucl Med. 2025. PMID: 39855939. doi:10.1053/j.semnuclmed.2025.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。